Skip to content

Study · Other design · 2002

3 results

Tripeptide Gly-His-Lys is a hepatotropic immunosuppressor.

Smakhtin MY, Sever'yanova LA, Konoplya AI, Shveinov IA

Bulletin of experimental biology and medicine1 Jun 2002Cited by 1 (Europe PMC)

PMID12447473 (opens in a new tab)DOI10.1023/a:1020242127443 (opens in a new tab)PepBankPUB-12447473
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalOther designEfficacy outcome

    In the reported injection study, Gly-His-Lys stimulated hepatocyte mitotic activity.

    In plain wordsIn the reported study, Gly-His-Lys injections increased hepatocyte division.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    IncreaseHepatocyte mitotic activity
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.5, 5, 50, 150, and 450 mg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Ten intraperitoneal injections of tripeptide Gly-His-Lys in doses of 1.5, 5, 50, 150, and 450 mg/kg stimulated mitotic activity of hepatocytes and dose-dependently suppressed immune reactivity (number of antibody-producing cells and delayed-type hypersensitivity reaction).
  2. 02AnimalOther designEfficacy outcome

    In the reported injection study, Gly-His-Lys dose-dependently suppressed the number of antibody-producing cells.

    In plain wordsIn the reported study, Gly-His-Lys injections reduced antibody-producing cells in a dose-dependent manner.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    DecreaseAntibody-producing cells
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.5, 5, 50, 150, and 450 mg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Ten intraperitoneal injections of tripeptide Gly-His-Lys in doses of 1.5, 5, 50, 150, and 450 mg/kg stimulated mitotic activity of hepatocytes and dose-dependently suppressed immune reactivity (number of antibody-producing cells and delayed-type hypersensitivity reaction).
  3. 03AnimalOther designEfficacy outcome

    In the reported injection study, Gly-His-Lys dose-dependently suppressed delayed-type hypersensitivity.

    In plain wordsIn the reported study, Gly-His-Lys injections reduced delayed-type hypersensitivity in a dose-dependent manner.

    Peptide
    GHK (glycyl-L-histidyl-L-lysine)
    Outcome
    DecreaseDelayed-type hypersensitivity
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.5, 5, 50, 150, and 450 mg/kg · intraperitonealAs given in this study.

    Source sentences

    Summary
    Ten intraperitoneal injections of tripeptide Gly-His-Lys in doses of 1.5, 5, 50, 150, and 450 mg/kg stimulated mitotic activity of hepatocytes and dose-dependently suppressed immune reactivity (number of antibody-producing cells and delayed-type hypersensitivity reaction).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.